nterococci are identified as the causative pathogen in approximately 10 percent of infective endocarditis cases, and the most frequently isolated species are Enterococcus faecalis and Enterococcus faecium (3) . Gentamicin in combination with penicillins or glycopeptides is recommended for enterococcal endocarditis treatment; however, the incidence of ototoxicity and nephrotoxicity with aminoglycosides is a concern, especially in older patients. Daptomycin is a cyclic lipopeptide with in vitro activity against a variety of Gram-positive pathogens, including Enterococcus spp., exhibiting a unique mechanism of action resulting in rapid bacterial cell death. However, development of resistance in enterococci with daptomycin monotherapy has been reported (1) . In vitro combinations of daptomycin and ampicillin have demonstrated a delayed ability to select out strains of Enterococcus with MICs of Ͼ4 g/ml after multiple serial passages (2). Sakoulas and colleagues reported a case of a hemodialysis patient with ampicillin-and vancomycin-resistant E. faecium left-sided endocarditis who failed on a combination of daptomycin (6 mg/kg of body weight every 48 h [q48h]) and linezolid. The patient then received a combination of daptomycin (12 mg/kg q48h) and ampicillin (1 g q6h), with blood cultures clearing within 24 h. Additional studies of this isolate demonstrated that ampicillin reduced the net positive bacterial surface charge for an increased bactericidal effect of daptomycin (4) . While the published clinical data on the treatment of enterococcal endocarditis using a combination of daptomycin and ampicillin are scarce, we feel that daptomycin plus ampicillin is a reasonable treatment option for enterococcal endocarditis, have integrated this combination into our treatment armamentarium, and have treated several patients successfully.
We report a case of an 89-year-old Caucasian female in good health but with a history of chronic hypertension and stage 4 chronic kidney disease (estimated baseline glomerular filtration rate [GFR] of 25 ml/min) who was admitted to the hospital after developing fever, generalized weakness, confusion, and an episode of cholelithiasis 2 weeks prior to the current admission. Levofloxacin was started empirically, and blood cultures were obtained. On day 2 of admission, blood cultures grew E. faecalis susceptible to daptomycin (MIC Յ 4 g/ml) and ampicillin. A transesophageal echocardiogram revealed a 0.89-by 1.4-cm mitral valve vegetation. Her cardiologist determined she was not a candidate for surgery. An infectious disease consult led to a decision to manage the patient medically. Levofloxacin was discontinued, and ampicillin (1 g q6h) and daptomycin (6 mg/kg q48h) were initiated with a goal of 6 weeks of therapy. Creatine phosphokinase was measured routinely throughout the 6 weeks, with no significant elevation noted. At week 6, blood cultures were negative and antibiotics were stopped, and repeat blood cultures 2 weeks later were also negative. Twelve months later, the patient was alive and had no clinical signs of endocarditis or active infection.
The combination of daptomycin and ampicillin yielded a successful outcome for treating E. faecalis endocarditis in this patient while providing an alternative to daptomycin monotherapy or an aminoglycoside-containing regimen. It has been suggested that doses higher than those approved by the FDA should be used to treat staphylococcal bacteremia; however, as shown here, when using an FDA-approved dose in combination with ampicillin, increased doses may not be necessary. Additional studies are needed to further explore this combination for the treatment of enterococcal endocarditis.
